Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001493152-22-035985
Filing Date
2022-12-20
Accepted
2022-12-20 16:00:18
Documents
1
Period of Report
2022-12-16

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 3656
  Complete submission text file 0001493152-22-035985.txt   5089
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Issuer) CIK: 0001859007 (see all company filings)

EIN.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZYVERSA THERAPEUTICS, INC. 2200 N. COMMERCE PARKWAY WESTON FL 33326
Business Address
Wolfe Peter (Reporting) CIK: 0001954398 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41184 | Film No.: 221474693